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Saudi Journal of Ophthalmology (2012) 26, 137–144Ophthalmic Pathology UpdateOcular melanomaBertil E. Damato, MD, PhD, FRCOphth a,⇑; Sarah E. Coupland, MBBS, PhD, FRCPath b,1AbstractOcular melanomas comprise uveal and conjunctival sub-types, which are very different from each other. A large majority of uveal
melanomas involve the choroid, with less than 10% being confined to the ciliary body and iris. They tend to metastasize haemat-
ogenously, almost always involving the liver. Therapeutic methods include various forms of radiotherapy, surgical resection and
phototherapy, which are often used in combination. Conjunctival melanomas show many similarities to their cutaneous counter-
parts, often metastasizing by lymphatic spread. Treatment consists of excision of invasive melanoma with adjunctive radiotherapy
and/or cryotherapy and topical chemotherapy for intra-epithelial disease. The management of patients with ocular melanomas
demands a good understanding of the pathology of these tumours. Pathological examination of the tumour indicates the prog-
nosis and hence the need for further investigation and treatment. The scope of the pathologist is enhanced thanks to advances in
molecular biology.
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Ocular melanomas are rare, especially in countries such
as Saudi Arabia. Nevertheless, it behoves clinicians to have
some knowledge of this disease so that when they encoun-
ter individuals with this condition they can offer the
standard of care that these patients deserve. Even though
such patients may be referred to an ocular oncology centre
overseas, the success of their management depends
greatly on the care that is provided at the home hospital,
which would include diagnosis, counselling and long-term
follow-up.
As with any disease, a good understanding of the
underlying pathology is fundamental to patient care. There
are many excellent sources of information on the pathol-
ogy of ocular melanomas; however, some articles havePeer review under responsibility
of Saudi Ophthalmological Society,
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Tel.: +44 151 706 5885; fax: +44 151 706 5859.become outdated because of rapid advances that have
occurred in recent years, and other texts are not easily
accessible.
The aims of this article are to provide a succinct yet prac-
tical overview of the pathology of ocular melanomas, with a
guide to the more detailed literature on the subject. It is
hoped that this review will be relevant not only to patholo-
gists but also to ophthalmologists and oncologists.Uveal melanoma
Introduction
Uveal melanomas account for approximately 98% of all
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and the remainder in the ciliary body.1
In Caucasians, uveal melanomas have an incidence of
approximately 7 per million per year.2 Presentation peaks
at the age of sixty years and is rare before adulthood. Males
and females are affected in equal numbers, although iris mel-
anomas tend to be slightly more common in women whereas
choroidal melanomas are more common in men.1
Risk factors for uveal melanoma include: light skin, blue
eyes, tendency to cutaneous naevi, congenital ocular melan-
ocytosis, uveal melanocytoma and neurofibromatosis. The
role of sunlight is uncertain but it is noteworthy that most iris
melanomas occur inferiorly, where there is less protection
from the upper eyelid.Histology
According to the modified Callendar classification, uveal
melanoma cytomorphology is categorized as: spindle; epi-
thelioid; and mixed. Spindle cells are long and narrow, with
large nuclei and nucleoli.3 They were previously called ‘spin-
dle-B’ cells to differentiate them from Spindle A cells with fur-
rowed nuclei, which are now considered to be benign.
Epithelioid cells are larger, with eosinophilic cytoplasm and
can be poorly cohesive (Fig. 1a). Rarely, the tumour is entirely
necrotic so that the cytomorphology is unclassifiable. Immu-
nohistochemistry staining of proteins such as Heat Shock Pro-
tein 27 (HSP-27) may be used for prognostic purposes
(Fig. 1b).4 Conventionally, mitoses are counted per forty
high-power fields using sections stained with haematoxylin
and eosin. (Fig. 1c). Other methods can be deployed, using
stains such as Ser-10 (also known as PHH3).5
Uveal melanomas often contain lymphocytes and macro-
phages, which are mentioned in reports because of theirFigure 1. Histopathology of uveal melanoma (a) haematoxylin and eosin slide
a good prognosis; (c) mitoses, stained with Ser-10 (PHH3)⁄; and (d) ‘‘closed’
(2011).15prognostic significance, greater numbers of such cells corre-
lating with increased mortality.
There are a variety of extravascular matrix patterns, best
shown using the periodic-acid schiff (PAS) reagent, without
counter-staining. The most significant are the so-called
‘closed loops’ (Fig. 1d), which correlate with aggressive
behaviour.6Molecular biology
Uveal melanomas tend to show a variety of non-random
chromosomal abnormalities. The most important of these
are: chromosome 3 loss, which can be partial or total (the lat-
ter being referred to as ‘monosomy 3’); chromosome 8q
gains, occurring either as isodisomy 8q or trisomy; and gains
in 6p, usually developing as a result of isochromosome for-
mation. These abnormalities tend to occur as a result of chro-
mosomal instability, with the abnormal separation of sister
chromatids during cell division. Chromosome 3 loss and 8q
gain are associated with a poor prognosis whereas chromo-
some 6p gain correlates with an improved survival
probability.7,8
On the basis of gene expression profiling, uveal melano-
mas have been categorized as ‘‘Class 1’’ and ‘‘Class 2’’, the
latter being associated with a high-risk of metastatic
disease.9
Mutations of guanine nucleotide-binding protein G(q) sub-
unit alpha (GNAQ) and GNA11 occur in a mutually-exclusive
pattern in about 80% of uveal melanomas.9 Mutations of the
BRCA1-associated protein (BAP1) on chromosome 3p21.1
are also common and these are associated with metastatic
disease.9,10showing epithelioid cells⁄; (b) staining for HSP-27, which is associated with
’ loops⁄. ⁄From Damato BE et al., Progress in Retinal and Eye Research
Figure 2. Fundus photographs of choroidal melanomas showing: (a) a small tumour with overlying lipofuscin pigment; (b) a large, dome-shaped tumour
with serous retinal detachment; (c) an amelanotic collar-stud melanoma; and (d) a diffuse melanoma.
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Choroidal melanomas initially form a dome-shaped
tumour (Fig. 2 a and b). There is an overlying retinal pig-
ment epitheliopathy, with the multilayering of retinal
pigment epithelial cells, lipofuscin accumulation, drusen
and retinal pigment epithelial detachment. In Caucasians,
most choroidal melanomas are amelanotic or only lightly
pigmented and it is the retinal pigment epithelial (RPE) pro-
liferation that gives choroidal melanomas their dark colour
(Fig. 2c). This RPE dysfunction causes retinal degeneration
and atrophy, inducing symptoms such as metamorphopsia,
blurring, visual field loss and photopsia. Many choroidal mel-
anomas rupture Bruch’s membrane and the retinal pigment
epithelium to prolapse into the sub-retinal space (Fig. 2c).
Strangulation of the herniated tumour by the rigid Bruch’s
membrane causes venous congestion and interstitial oede-
ma so that the tumour develops a collar-stud or mushroom
shape, which is virtually pathognomonic for choroidal
melanoma. Some tumours invade the retina, eventually
perforating this structure to reach the vitreous, possibly
resulting in vitreous haemorrhage and, rarely, seeding of
tumour cells around the eye. Intraocular spread of tumour
can occur anteriorly to involve the ciliary body, iris and
angle, as well as posteriorly, towards the optic disc, which
however is only rarely invaded.
Approximately, 5% of choroidal melanomas are diffuse,
spreading thinly around the uvea without forming any thick
nodules (Fig. 2d).
Ciliary body melanomas behave in a similar fashion to cho-
roidal tumours. Indeed, it is often difficult to determine
whether a choroidal melanoma has invaded the ciliary body
or vice versa. These tumours tend to impinge on the lens to
cause astigmatism, cataract and subluxation. The overlying
episcleral vessels tend to become dilated and tortuous (i.e.,‘sentinel vessels’). Anterior spread often occurs into the ante-
rior chamber (Fig. 3a). There also tends to be circumferential
spread around the ciliary body, iris and angle (i.e., ‘ring mel-
anoma’). Such circumferential spread can be diffuse and ini-
tially sub-clinical so that when treating such anterior
tumours it is necessary to apply very wide lateral safety
margins.
The secondary retinal detachment can become bullous
and, eventually, total. As with other causes of serous retinal
detachment, there is no proliferative vitreoretinopathy so
that the retina is smooth and mobile. Detached retina tends
to be ischaemic and produces vasoproliferative factors,
which, together with those emanating from the tumour, in-
duce rubeosis and neovascular glaucoma. Infarction of the tu-
mour can occur, causing uveitis, which can be severe enough
to amount to panophthalmitis, with orbital cellulitis and eye-
lid swelling.
Iris melanomas can be nodular or diffuse or mixed
(Fig. 3b–d). Some have a multinodular appearance (i.e., ‘tap-
ioca melanoma’). The nodular melanomas tend to cause adja-
cent sectorial cataract and keratopathy if they come into
contact with a large area of the endothelium. Diffuse melano-
mas spread widely, and if they extend around the angle they
tend to cause secondary glaucoma. Seeding of tumour cells
around the iris and angle can occur (Fig. 3d). Iris melanomas
can spread posteriorly into the ciliary body, some reaching
the choroid.
If left untreated, intraocular melanomas result in a blind,
painful, and unsightly eye.
Extraocular spread
At any stage, uveal melanomas can spread extra-ocularly.
Such spread tends to occur through pre-existing channels for
ciliary arteries, vortex veins and drainage vessels.11 Extraocu-
Figure 3. Slit-lamp appearances of anterior uveal melanomas, showing: (a) a ciliary body melanoma extending into anterior chamber; (b) a pigmented,
nodular iris melanoma; (c) an amelanotic, nodular iris melanoma⁄; and (d) a diffuse iris melanoma with seeding. ⁄From Ocular Tumours, B Damato.
Butterworth Heinemann (2000).
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Tenon’s fascia, or diffuse. If neglected, orbital spread can
become extensive enough to cause proptosis. Before the
twentieth century, it was not uncommon for uveal melanoma
to spread through the optic canal into the cranial cavity to in-
volve the brain.
Metastatic disease
Almost 50% of all patients with uveal melanoma develop
metastatic disease, which usually becomes manifest from the
second post-operative year onwards.12 Only about 2% of all
patients have detectable metastases when their ocular tumour
is diagnosed and treated. Metastatic disease almost always in-
volves the liver, less common sites being the lungs, skin and
bone. Regional lymph nodes are rarely involved, even when
the tumour shows extraocular spread. Most patients with
metastases die within a year of the onset of symptoms, but
long-term survivors are becoming more common thanks to ad-
vances such as partial hepatectomy, ipilimumab, selective
internal radiotherapy with yttrium beads, and intra-hepatic
chemotherapy, particularly using systems for isolated liver per-
fusion. These developments have increased the scope of
screening for metastatic disease by a variety of imaging meth-
ods, such as hepatic magnetic resonance imaging, and blood
tests, such as liver function tests and circulating melanoma
cells.13,14
Prognostication
As with other cancers, prognostication is an important as-
pect of patient care, identifying high-risk patients requiring
special care while allowing low-risk patients to be reassuredof their good survival prospects. The pathologist is well-
placed to play a valuable role in this process. This is because
histological grade of malignancy and genetic type of mela-
noma profoundly influence prognosis.15
The clinical features associated most strongly with an in-
creased risk of metastatic disease from posterior segment
melanoma are: largest basal tumour diameter; tumour
height; ciliary body involvement; and extraocular spread.
These form the basis of the 7th edition of the TNM staging
system (i.e., Tumour, Node, Metastasis system developed
by the American Joint Committee on Cancer).16 With iris mel-
anomas, risk factors for metastasis include diffuse spread, an-
gle involvement and secondary glaucoma.17
Histological predictors of metastasis include: melanoma
cytomorphology; mitotic count; and the presence of closed
loops. There is no consensus as to the proportion of mela-
noma cells that need to show epithelioid cytomorphology
before the melanoma is termed ‘‘epithelioid’’. We report
the approximate percentage of epithelioid cells within a
melanoma.
Metastatic disease occurs almost exclusively with melano-
mas showing chromosome 3 loss and/or class 2 gene expres-
sion profile, which correlate strongly with each other.9 The
survival prognosis is especially poor when chromosome 3 loss
and chromosome 8q gain occur together.8,18 Conversely,
chromosome 6p gain is associated with a better prognosis,
partly because chromosome 3 loss is less common in the
presence of 6p gain and also because the survival time is
longer.19
Chromosomal testing with fluorescence in situ hybridisa-
tion has largely been superseded by more sensitive methods
such as multiplex ligation-dependent probe amplification
(MLPA), microsatellite analysis (MSA), array comparative
Figure 4. Kaplan–Meier survival curves showing survival according to the
presence or absence of chromosome 3 loss, determined by multiplex
ligation-dependent probe amplification.
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ing.8,20–24 At present, we use MLPA as a first-line test, with
MSA if the tumour sample is small or has a low DNA concen-
tration (Fig. 4).
We have developed mathematical tools for estimating the
survival prognosis after treatment of the choroidal mela-
noma.15 These integrate the pathological grade of malig-Figure 5. Personalised prognostication integrating pathological findings with
by subtracting the all-cause mortality of the general population (upper curve)nancy with TNM clinical stage and with chromosome 3 loss,
also taking age and sex into account (i.e., normal life expec-
tancy) (Fig. 5). Our method adjusts for competing risks and
generates survival curves that are accurate enough to be
relevant to individual patients. This program is available
online, free of charge (www.ocularmelanomaonline.com).
Conjunctival melanoma
Introduction
Conjunctival melanomas comprise about 2% of all ocular
melanomas and are therefore very rare, even in Caucasians.
As with uveal melanomas, they occur in adulthood, particu-
larly in later life, and the incidence is similar in both sexes.25
Risk factors include: fair skin; tendency to sunburn and to
have a relatively-high number of cutaneous naevi.
Histology
Conjunctival melanomas arise from intra-epithelial mela-
nocytes, which are normally located in the basal layer of the
epithelium and which have long dendritic processes supply-
ing melanin pigment to adjacent epithelial cells. On malig-
nant transformation, melanocytes lose their dendrites and
demonstrate atypical features such as epithelioid morphol-
ogy, with a large nucleus and prominent nucleolus (Fig. 6).
In addition, they increase in number and invade the more
superficial layers of the conjunctival epithelium, forming sep-
arate and confluent cells nests and increasing in density until
most of the epithelium is replaced by atypical melanocytes.
The rate of cellular proliferation by the neoplastic melano-genetic results and clinical tumour stage. The metastatic risk is estimated
from that of the patient population (lower curve).
Figure 6. Histological grading of conjunctival melanocytic intra-epithelial neoplasia (C-MIN). From Damato B and Coupland SE. Management of
conjunctival melanoma. Expert Rev. Anticancer Ther. 2009;9:1227–39.
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Eventually, the surface of the epithelium becomes ‘‘ulcer-
ated’’. Previously, this condition was referred to as ‘primary
acquired melanosis (PAM) with atypia’26; however, such
terminology is imprecise because it subsumes two patholog-
ical processes: both (a) melanin over-production (i.e., ‘hyper-
melanosis’) and (b) proliferation of atypical melanocytes (i.e.
melanocytosis). We prefer the term ‘conjunctival melanocytic
intra-epithelial neoplasia (C-MIN)’, which we describe as
occurring with and without atypia, according to whether or
not the melanocytes show atypical cytological features and
whether they demonstrate particular radial and vertical
growth patterns.27 We have developed a system for scoring
the degree of atypia according to these features (Fig. 5), with
the maximum score being 10.27 We have also introduced the
term ‘conjunctival melanoma in situ’, which refers to the more
severe grades of C-MIN (i.e., score > 5).
Invasive melanoma is present when the conjunctival base-
ment membrane has been breached by the neoplastic mela-
nocytes resulting in invasion of the lamina propria. This
development is of fundamental prognostic significance as
the tumour cells have gained access to lymphatic channels
and blood vessels, thereby giving rise to a possibility of met-
astatic disease. Tumour-associated lymphangiogenesis corre-
lates with increased mortality.28
Other notable histological features, which are of prognos-
tic value, include lymphocytic infiltration, tumour thickness,
surface ulceration, depth of invasion, and surgical clearance.
The presence of pagetoid spread in the epithelium is also sig-
nificant as it indicates an increased risk of local recurrence,
thereby influencing ocular treatment.Molecular biology
Conjunctival melanomas are biologically different from
their uveal counterparts and are more similar to cutaneous
and mucous membrane melanomas. We and many others
have shown, for example, that conjunctival melanomas com-monly show BRAF V600E mutations, which do not occur with
intraocular melanomas.29 Such BRAF mutations are of clinical
significance because they indicate that the patient may re-
spond to treatment with vemurafenib, should metastatic dis-
ease develop.30 Other mutations include CDKN1A, RUNX2,
MLH1, TIMP2, MGMT, ECHS1 and others.29 To our knowl-
edge, none of these factors have yet been shown to have
prognostic value.
Pathophysiology
Conjunctival melanomas can be described as ‘in situ’ or
‘invasive’. Invasive melanomas can arise de novo, from a
pre-existing naevus, or from pre-existing C-MIN (Fig. 7).
Most invasive conjunctival melanomas arise in the bulbar con-
junctiva, especially temporally, less common sites of origin
being the caruncle, plica and tarsal conjunctiva.31–33 They
can be nodular, diffuse or mixed and single or multiple.
The degree of pigmentation is highly variable between tu-
mours, even within the same patient, so that clinically the col-
our of the melanomas can be black, grey, brown, pink, red,
yellow or white. Dilated conjunctival feeder vessels are com-
monly present.
Local spread
Conjunctival melanomas can show pagetoid spread within
the epithelium, seeding across the conjunctival surface and
into the nasolacrimal passages, and invasion within the con-
junctiva as well as to the surrounding tissues. Such invasion
can occur circumferentially along the limbus and fornix, as
well as deeply into the eye, orbit, sinuses, and cranial cavity.
They can also invade the adjacent skin. Intraocular spread is
more likely after inadequate surgery, especially if there is dis-
ruption of the Bowman’s membrane, which serves as a natu-
ral barrier.34 Seeding can be iatrogenic, with the transfer of
malignant cells to healthy tissues by means of contaminated
surgical instruments.
Figure 7. Slit-lamp photographs showing: (a) conjunctival melanocytic intraepithelial neoplasia; (b) diffuse, invasive conjunctival melanoma; (c) bulbar
invasive conjunctival melanoma; and (d) caruncular invasive conjunctival melanoma. From Damato B and Coupland SE. Management of conjunctival
melanoma. Expert Rev. Anticancer Ther. 2009;9:1227–39.
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Metastases can occur via lymphatics to regional lymph
nodes and haematogenously to other parts of the body.35,36
Risk factors predicting metastatic disease include:
involvement of non-bulbar conjunctiva, particularly the carun-
cle; tumour thickness; histological grade of malignancy; and
histological evidence of lymphatic invasion.37–39,39,40Prognostication
The 7th edition of the TNM staging system categorizes the
clinical stage of conjunctival melanomas according to circum-
ferential spread, in terms of: (1) number of quadrants of con-
junctiva involved; (2) location in bulbar or extra-bulbar
conjunctiva; (3) caruncular involvement; and (4) invasion of
the substantia propria, globe, eyelid, orbit, sinus and CNS.
Approximately 20% of all patients with conjunctival mela-
noma die of metastatic disease within ten years, but mortality
is much higher if the caruncle is involved.39,37Conclusions
The management of patients with an ocular melanoma de-
pends greatly on proper understanding of the pathology of
their tumour. Pathological examination of ocular melanomas
profoundly influences patient care, not only confirming the
diagnosis but also indicating prognosis and hence the need
for further investigation and treatment. The role of the pathol-
ogist is growing thanks to advances in molecular biology and
the involvement of pathologists in this specialized field.References
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